Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly— Preliminary results of the GIM-13 AMBRA study.

e13078Background: Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP) and greater overall survival (OS) in ABC pts treated with second-line or greater therapy. The improved safety and efficacy profile for Nab-P compared with solvent-based taxanes suggests that Nab-P may be particularly useful in older patients. A post-hoc analysis showed that weekly Nab-P (wNab-P) was safe and more efficacious in comparison to the q3w schedule and with solvent-based taxanes in older patients with ABC. Aim of the present analysis is to describe the use of Nab-P in the elderly (≥ 65 years) population registered in the GIM-13 AMBRA study. Methods: AMBRA is a longitudinal cohort study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve ABC pts receiving at least one CHT (SABCS 2016, P5-15-07 & P5-14-09) in the years 2012-2015. For the present analysis, we focused on the use of Nab-P pts aged ≥ 65 years. Re...